Genetic Algorithm Managed Peptide Mutant Screening: Optimizing Peptide Ligands for Targeted Receptor Binding.

Area of Science:

• Biochemistry
• Computational Biology
• Pharmacology

Background:

• Discovering high-affinity ligands for specific receptors is crucial in drug development.
• Large mutant libraries offer potential but are challenging to screen comprehensively.
• Alpha-conotoxin MII (α-CTx MII) is a potent ligand for nicotinic acetylcholine receptors (nAChRs).

Purpose of the Study:

• To demonstrate the utility of genetic algorithms for searching large mutant peptide libraries.
• To identify novel α-CTx MII peptide sequences with enhanced binding affinity for the α3β2-nicotinic acetylcholine receptor (nAChR) isoform.
• To evaluate the efficiency of the Genetic Algorithm Managed Peptide Mutant Screening (GAMPMS) program.

Main Methods:

• Utilized the Genetic Algorithm Managed Peptide Mutant Screening (GAMPMS) program.
• Screened an α-conotoxin MII mutant library of approximately 41 billion sequences.
• Performed rigorous binding free energy calculations using molecular dynamics on selected consensus sequences.

Main Results:

• Identified a series of top peptide ligands with high sequence homology and significantly enhanced binding affinity.
• Obtained mutants with an estimated binding free energy (ΔGbind) approximately double that of the native α-CTx MII.
• Demonstrated substantial reduction in the sample population size through evolutionary selection.

Conclusions:

• GAMPMS is an efficient tool for navigating exceptionally large mutant libraries.
• The identified peptide ligands exhibit superior binding affinity to the α3β2-nAChR compared to the native ligand.
• This approach accelerates the discovery of high-affinity peptide therapeutics.